Research and develop innovative pharmaceuticals. Manufacture and sell prescription medications. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
If every debt were paid off today, $387.8M would still be left in the vault — a solid cushion for hard times.
The market pays 34× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 6 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 62% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $1.6B in the vault; even if every debt were paid off, $387.8M would remain.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.
Against everything we grade, ESAIY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: ESAIY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.